Cite
Koay EJ, Katz MHG, Wang H, et al. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol. 2019;3doi: 10.1200/PO.19.00001.
Koay, E. J., Katz, M. H. G., Wang, H., Wang, X., Prakash, L., Javle, M., Shroff, R., Fogelman, D., Avila, S., Zaid, M., Elganainy, D., Lee, Y., Crane, C. H., Krishnan, S., Das, P., Fleming, J. B., Lee, J. E., Tamm, E. P., Bhosale, P., Lee, J. H., Weston, B., Maitra, A., Wolff, R. A., & Varadhachary, G. R. (2019). Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO precision oncology, 3. https://doi.org/10.1200/PO.19.00001
Koay, Eugene J, et al. "Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer." JCO precision oncology vol. 3 (2019). doi: https://doi.org/10.1200/PO.19.00001
Koay EJ, Katz MHG, Wang H, Wang X, Prakash L, Javle M, Shroff R, Fogelman D, Avila S, Zaid M, Elganainy D, Lee Y, Crane CH, Krishnan S, Das P, Fleming JB, Lee JE, Tamm EP, Bhosale P, Lee JH, Weston B, Maitra A, Wolff RA, Varadhachary GR. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol. 2019 Aug 23;3. doi: 10.1200/PO.19.00001. eCollection 2019. PMID: 32914036; PMCID: PMC7446521.
Copy
Download .nbib